AUG 12, 2021 7:00 AM PDT

Anticoagulants Target a Weak Spot in Coronavirus Variants

WRITTEN BY: Tara Fernandez

Australian researchers have found a new molecular binding site on the coronavirus that causes COVID-19, a discovery that paves the way for new drug targets to treat COVID-19.

The virus’ spike protein binds to heparan sulfate on the surface of host cells, which forms the first step in the infection cascade. This interaction has been in the research spotlight as scientists scrambled to identify drugs, vaccines, and antibodies capable of blocking the spike protein’s receptor-binding domain, or RBD, from latching onto human cells.

Now, scientists discovered a novel binding site on a different region of the coronavirus’ spike protein known as the N-terminal domain (NTD). SARS-CoV-2 variants often have mutations in this NTD site.

Antibodies produced by patients that recovered from COVID-19 were found to bind to the NTD to neutralize the virus. This clue led the research team to hypothesize that the same site could be targeted to stop the virus from infecting human cells.

“Therefore, targeting the NTD site with molecules like heparin (or heparin mimetics), a known anticoagulant drug similar to HS, is a possible strategy to stop the virus binding to cells and infecting them,” explained Zachariah Schuurs, one of the investigators. Anticoagulants are typically administered to prevent blood clots and reduce patients’ chances of developing life-threatening conditions such as strokes and heart attacks.

According to the researchers, there is an urgent need to expand our current arsenal of therapeutic weapons against the coronavirus, particularly given the rapid spread of dangerous SARS-CoV-2 variants. Vaccine coverage is still low in many parts of the world, increasing the likelihood that vaccine-resistant variants will emerge. Indeed, variants of concern that are more contagious and cause more severe infections have emerged throughout the pandemic.

In their study, the scientists used 3-dimensional molecular mapping techniques to show how negatively charged heparin (an anticoagulant molecule) could bind to positively charged mutations in the spike protein. This opens the door to heparin being used as a potential broad-spectrum antiviral drug against current and emerging SARS-CoV-2 variants.

 



Sources: QUT News, Computational and Structural Biotechnology Journal.

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
JUL 27, 2021
Health & Medicine
No Link Found Between Vaccinations and Increased Risk of Allergic Diseases
JUL 27, 2021
No Link Found Between Vaccinations and Increased Risk of Allergic Diseases
It is well known that allergies and asthma have been on the rise in developed nations where childhood mass vaccinations ...
JUL 29, 2021
Drug Discovery & Development
What is Ivermectin and Can it Treat COVID?
JUL 29, 2021
What is Ivermectin and Can it Treat COVID?
Lab tests in 2020 found that the widely available drug ivermectin had a weak effect on the SARS-CoV-2 virus and that unf ...
AUG 05, 2021
Immunology
Nosedive: Poor Nasal Antiviral Responses Linked to Severe COVID
AUG 05, 2021
Nosedive: Poor Nasal Antiviral Responses Linked to Severe COVID
Talking, singing, coughing—all of these can spread COVID-19 from an infected person via respiratory aerosols. Thes ...
AUG 16, 2021
Coronavirus
Why is the Delta variant causing more infections?
AUG 16, 2021
Why is the Delta variant causing more infections?
New research suggests that the Delta variant is more infectious than the original COVID-19 virus.
AUG 26, 2021
Coronavirus
Researchers View COVID-19 Progression in a Live Animal Model
AUG 26, 2021
Researchers View COVID-19 Progression in a Live Animal Model
Scientists have used a mouse model to visualize the progression of a SARS-CoV-2 infection as it led to sometimes fatal c ...
SEP 14, 2021
Health & Medicine
Graphene-Oxide Based Nanotechnology and Immunology-An Exciting Partnership
SEP 14, 2021
Graphene-Oxide Based Nanotechnology and Immunology-An Exciting Partnership
As treatments and infection control practices surrounding COVID-19 continue to evolve, nanotechnological solutions are b ...
Loading Comments...